Methods and compositions for inhibiting diseases of the central nervous system
Methods and compositions for treating central nervous system diseases and disorders are disclosed.
1. A method of treating a central nervous system disease or disorder in a patient in need thereof, wherein said central nervous system disease or disorder is characterized by the presence of at least one abnormal protein, said method comprising administering to said patient:
a) at least one immunogen capable of inducing a humoral immune response against said abnormal protein, and
b) at least one adjuvant that stimulates regulatory T cells, wherein said central nervous disease or disorder is amyotrophic lateral sclerosis (ALS) and said immunogen is superoxide dismutase (SOD).
2. The method of claim 1 , wherein said adjuvant is selected from the group consisting of glatiramer acetate, vasoactive intestinal peptide, vitamin D, granulocyte macrophage colony stimulating factor, and transforming growth factor beta.
3. The method of claim 2 , wherein said adjuvant is vasoactive intestinal peptide.
4. The method of claim 1 , wherein said adjuvant is selected from the group consisting of vasoactive intestinal peptide, vitamin D, granulocyte macrophage colony stimulating factor, and transforming growth factor beta.
5. The method of claim 1 , wherein said immunogen and said adjuvant are in a single composition, wherein said composition, optionally, further comprises at least one pharmaceutically acceptable carrier.
6. The method of claim 1 , wherein said immunogen and said adjuvant are in separate compositions, wherein each composition, optionally, further comprises at least one pharmaceutically acceptable carrier.
7. The method of claim 6 , wherein said separate compositions are administered simultaneously.
8. The method of claim 6 , wherein said separate compositions are administered sequentially.